{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:16:56Z","timestamp":1788430616384,"version":"build-2803163510"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00415-026-14023-5","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:44:28Z","timestamp":1785595468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting TDP-43 in sporadic amyotrophic lateral sclerosis"],"prefix":"10.1007","volume":"273","author":[{"given":"Carlos","family":"Estevez-Fraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Alvarez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Afroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos R.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jovi\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix L","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McColgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"McCampbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"5\u20136","key":"14023_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/17482960802566824","volume":"10","author":"A Chi\u00f2","year":"2009","unstructured":"Chi\u00f2 A et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10(5\u20136):310\u2013323. https:\/\/doi.org\/10.3109\/17482960802566824","journal-title":"Amyotroph Lateral Scler"},{"key":"14023_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-022-00564-x","author":"TW Todd","year":"2022","unstructured":"Todd TW, Petrucelli L (2022) Modelling amyotrophic lateral sclerosis in rodents. Nat Rev Neurosci. https:\/\/doi.org\/10.1038\/s41583-022-00564-x","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"14023_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"K Abe","year":"2017","unstructured":"Abe K et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505\u2013512. https:\/\/doi.org\/10.1016\/S1474-4422(17)30115-1","journal-title":"Lancet Neurol"},{"issue":"3","key":"14023_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/mus.28448","volume":"72","author":"J Rothstein","year":"2025","unstructured":"Rothstein J et al (2025) Efficacy and safety of once daily dosing vs. approved on\/off dosing of edaravone oral suspension up to 48\u2009weeks in patients with amyotrophic lateral sclerosis (Study MT-1186-A02). Muscle Nerve 72(3):433\u2013442. https:\/\/doi.org\/10.1002\/mus.28448","journal-title":"Muscle Nerve"},{"issue":"2","key":"14023_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41582-024-01049-4","volume":"21","author":"KME Faller","year":"2025","unstructured":"Faller KME, Chaytow H, Gillingwater TH (2025) Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis. Nat Rev Neurol 21(2):86\u2013102. https:\/\/doi.org\/10.1038\/s41582-024-01049-4","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"14023_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41583-021-00431-1","volume":"22","author":"P Tziortzouda","year":"2021","unstructured":"Tziortzouda P, Van Den Bosch L, Hirth F (2021) Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci 22(4):197\u2013208. https:\/\/doi.org\/10.1038\/s41583-021-00431-1","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"14023_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nn.2779","volume":"14","author":"M Polymenidou","year":"2011","unstructured":"Polymenidou M et al (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14(4):459\u2013468. https:\/\/doi.org\/10.1038\/nn.2779","journal-title":"Nat Neurosci"},{"issue":"3","key":"14023_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","volume":"79","author":"S-CC Ling","year":"2013","unstructured":"Ling S-CC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79(3):416\u2013438. https:\/\/doi.org\/10.1016\/j.neuron.2013.07.033","journal-title":"Neuron"},{"issue":"5796","key":"14023_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130\u2013133. https:\/\/doi.org\/10.1126\/science.1134108","journal-title":"Science"},{"issue":"1","key":"14023_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00401-016-1633-2","volume":"133","author":"H Braak","year":"2017","unstructured":"Braak H, Ludolph AC, Neumann M, Ravits J, Del Tredici K (2017) Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal \u03b1-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol 133(1):79\u201390. https:\/\/doi.org\/10.1007\/s00401-016-1633-2","journal-title":"Acta Neuropathol"},{"issue":"2","key":"14023_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/glia.24096","volume":"70","author":"KE Prater","year":"2022","unstructured":"Prater KE, Latimer CS, Jayadev S (2022) Glial TDP\u201043 and TDP\u201043 induced glial pathology, focus on neurodegenerative proteinopathy syndromes. Glia 70(2):239\u2013255. https:\/\/doi.org\/10.1002\/glia.24096","journal-title":"Glia"},{"key":"14023_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012508","author":"Y Tamaki","year":"2022","unstructured":"Tamaki Y, Urushitani M (2022) Molecular dissection of TDP-43 as a leading cause of ALS\/FTLD. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232012508","journal-title":"Int J Mol Sci"},{"issue":"2","key":"14023_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1750-3639.2009.00284.x","volume":"20","author":"MT Giordana","year":"2010","unstructured":"Giordana MT et al (2010) TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol 20(2):351\u2013360. https:\/\/doi.org\/10.1111\/j.1750-3639.2009.00284.x","journal-title":"Brain Pathol"},{"issue":"1","key":"14023_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62482-7","volume":"16","author":"JD Rothstein","year":"2025","unstructured":"Rothstein JD et al (2025) Sporadic ALS induced pluripotent stem cell derived neurons reveal hallmarks of TDP-43 loss of function. Nat Commun 16(1):7092. https:\/\/doi.org\/10.1038\/s41467-025-62482-7","journal-title":"Nat Commun"},{"issue":"6248","key":"14023_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.aab0983","volume":"349","author":"JP Ling","year":"2015","unstructured":"Ling JP, Pletnikova O, Troncoso JC, Wong PC (2015) TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349(6248):650\u2013655. https:\/\/doi.org\/10.1126\/science.aab0983","journal-title":"Science"},{"issue":"2","key":"14023_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","volume":"22","author":"Z Melamed","year":"2019","unstructured":"Melamed Z et al (2019) Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci 22(2):180\u2013190. https:\/\/doi.org\/10.1038\/s41593-018-0293-z","journal-title":"Nat Neurosci"},{"issue":"11","key":"14023_CR17","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1172\/JCI139741","volume":"130","author":"M Prudencio","year":"2020","unstructured":"Prudencio M et al (2020) Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest 130(11):6080\u20136092. https:\/\/doi.org\/10.1172\/JCI139741","journal-title":"J Clin Invest"},{"issue":"7899","key":"14023_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","volume":"603","author":"AL Brown","year":"2022","unstructured":"Brown AL et al (2022) TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603(7899):131\u2013137. https:\/\/doi.org\/10.1038\/s41586-022-04436-3","journal-title":"Nature"},{"issue":"2","key":"14023_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41593-017-0047-3","volume":"21","author":"C-C Chou","year":"2018","unstructured":"Chou C-C et al (2018) TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS\/FTD. Nat Neurosci 21(2):228\u2013239. https:\/\/doi.org\/10.1038\/s41593-017-0047-3","journal-title":"Nat Neurosci"},{"issue":"8","key":"14023_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/jnen\/nlad042","volume":"82","author":"S Koga","year":"2023","unstructured":"Koga S, Murakami A, Martin NB, Dickson DW (2023) The frequency and distribution of TDP-43 pathology in argyrophilic grain disease. J Neuropathol Experimental Neurol 82(8):739\u2013741. https:\/\/doi.org\/10.1093\/jnen\/nlad042","journal-title":"J Neuropathol Experimental Neurol"},{"issue":"23","key":"14023_CR21","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1093\/hmg\/ddt319","volume":"22","author":"W Wang","year":"2013","unstructured":"Wang W et al (2013) The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum Mol Genet 22(23):4706\u20134719. https:\/\/doi.org\/10.1093\/hmg\/ddt319","journal-title":"Hum Mol Genet"},{"issue":"2","key":"14023_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1523\/JNEUROSCI.4988-09.2010","volume":"30","author":"SJ Barmada","year":"2010","unstructured":"Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S (2010) Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 30(2):639\u2013649. https:\/\/doi.org\/10.1523\/JNEUROSCI.4988-09.2010","journal-title":"J Neurosci"},{"issue":"8","key":"14023_CR23","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1073\/pnas.0912417107","volume":"107","author":"H Wils","year":"2010","unstructured":"Wils H et al (2010) TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 107(8):3858\u20133863. https:\/\/doi.org\/10.1073\/pnas.0912417107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"14023_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00401-015-1460-x","volume":"130","author":"AK Walker","year":"2015","unstructured":"Walker AK et al (2015) Functional recovery in new mouse models of ALS\/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol 130(5):643\u2013660. https:\/\/doi.org\/10.1007\/s00401-015-1460-x","journal-title":"Acta Neuropathol"},{"key":"14023_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz078","author":"RC Hergesheimer","year":"2019","unstructured":"Hergesheimer RC, Chami AA, De Assis DR, Vourc P, Andres CR, Corcia P (2019) The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis\u202f: a resolution in sight\u202f? Aggregated TDP-43 is a hallmark for ALS: patient. Brain. https:\/\/doi.org\/10.1093\/brain\/awz078","journal-title":"Brain"},{"issue":"5","key":"14023_CR26","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1074\/jbc.M112.407726","volume":"288","author":"J-Q Wang","year":"2013","unstructured":"Wang J-Q et al (2013) Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease. J Biol Chem 288(5):3070\u20133084. https:\/\/doi.org\/10.1074\/jbc.M112.407726","journal-title":"J Biol Chem"},{"key":"14023_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007947","author":"P Wang","year":"2019","unstructured":"Wang P et al (2019) TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. https:\/\/doi.org\/10.1371\/journal.pgen.1007947","journal-title":"PLoS Genet"},{"key":"14023_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2021.653688","volume":"15","author":"C Als","year":"2021","unstructured":"Als C, Dafinca R, Barbagallo P, Talbot K (2021) The role of mitochondrial dysfunction and ER stress in TDP-43. Front Cell Neurosci 15:1\u20139. https:\/\/doi.org\/10.3389\/fncel.2021.653688","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"14023_CR29","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.celrep.2019.04.003","volume":"27","author":"EY Liu","year":"2019","unstructured":"Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB (2019) Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. Cell Rep 27(5):1409-1421.e6. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.003","journal-title":"Cell Rep"},{"issue":"11","key":"14023_CR30","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1038\/s41593-025-02049-3","volume":"28","author":"Y Zeng","year":"2025","unstructured":"Zeng Y et al (2025) TDP-43 nuclear loss in FTD\/ALS causes widespread alternative polyadenylation changes. Nat Neurosci 28(11):2180\u20132189. https:\/\/doi.org\/10.1038\/s41593-025-02049-3","journal-title":"Nat Neurosci"},{"issue":"11","key":"14023_CR31","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/s41593-025-02050-w","volume":"28","author":"S Bryce-Smith","year":"2025","unstructured":"Bryce-Smith S et al (2025) TDP-43 loss induces cryptic polyadenylation in ALS\/FTD. Nat Neurosci 28(11):2190\u20132200. https:\/\/doi.org\/10.1038\/s41593-025-02050-w","journal-title":"Nat Neurosci"},{"issue":"8","key":"14023_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nchembio.1563","volume":"10","author":"SJ Barmada","year":"2014","unstructured":"Barmada SJ et al (2014) Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol 10(8):677\u2013685. https:\/\/doi.org\/10.1038\/nchembio.1563","journal-title":"Nat Chem Biol"},{"issue":"2","key":"14023_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1172\/JCI44867","volume":"121","author":"LM Igaz","year":"2011","unstructured":"Igaz LM et al (2011) Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 121(2):726\u2013738. https:\/\/doi.org\/10.1172\/JCI44867","journal-title":"J Clin Invest"},{"issue":"1","key":"14023_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13041-023-01050-w","volume":"16","author":"A Onda-Ohto","year":"2023","unstructured":"Onda-Ohto A et al (2023) Specific vulnerability of iPSC-derived motor neurons with TDP-43 gene mutation to oxidative stress. Mol Brain 16(1):62. https:\/\/doi.org\/10.1186\/s13041-023-01050-w","journal-title":"Mol Brain"},{"key":"14023_CR35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.95062.2","author":"J Ganssauge","year":"2025","unstructured":"Ganssauge J, Hawkins S, Namboori SC, Leung SK, Mill J, Bhinge A (2025) Rapid and inducible mislocalization of endogenous TDP43 in a novel human model of amyotrophic lateral sclerosis. eLife. https:\/\/doi.org\/10.7554\/eLife.95062.2","journal-title":"Elife"},{"issue":"2","key":"14023_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00335-025-10131-1","volume":"36","author":"JMB Armas","year":"2025","unstructured":"Armas JMB, Taoro-Gonz\u00e1lez L, Fisher EMC, Acevedo-Arozena A (2025) Challenges of modelling TDP-43 pathology in mice. Mamm Genome 36(2):465\u2013481. https:\/\/doi.org\/10.1007\/s00335-025-10131-1","journal-title":"Mamm Genome"},{"issue":"9","key":"14023_CR37","doi-asserted-by":"publisher","first-page":"6826","DOI":"10.1074\/jbc.M109.061846","volume":"285","author":"CF Sephton","year":"2010","unstructured":"Sephton CF et al (2010) TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem 285(9):6826\u20136834. https:\/\/doi.org\/10.1074\/jbc.M109.061846","journal-title":"J Biol Chem"},{"issue":"6","key":"14023_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112648","volume":"28","author":"BA Evangelista","year":"2025","unstructured":"Evangelista BA et al (2025) ALS-associated TDP-43 aggregates drive innate and adaptive immune cell activation. iScience 28(6):112648. https:\/\/doi.org\/10.1016\/j.isci.2025.112648","journal-title":"iScience"},{"issue":"7899","key":"14023_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","volume":"603","author":"XR Ma","year":"2022","unstructured":"Ma XR et al (2022) TDP-43 represses cryptic exon inclusion in the FTD\u2013ALS gene UNC13A. Nature 603(7899):124\u2013130. https:\/\/doi.org\/10.1038\/s41586-022-04424-7","journal-title":"Nature"},{"key":"14023_CR40","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.20.599684","author":"MJ Keuss","year":"2024","unstructured":"Keuss MJ et al (2024) Loss of TDP-43 induces synaptic dysfunction that is rescued by UNC13A splice-switching ASOs. bioRxiv.\u00a0https:\/\/doi.org\/10.1101\/2024.06.20.599684","journal-title":"bioRxiv Prepr Serv Biol"},{"issue":"5\u20136","key":"14023_CR41","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/21678421.2024.2447922","volume":"26","author":"C Novy","year":"2025","unstructured":"Novy C et al (2025) Association of UNC13A with increased amyotrophic lateral sclerosis risk, bulbar onset, and lower motor neuron involvement in a Norwegian ALS cohort. Amyotroph Lateral Scler Frontotemporal Degener 26(5\u20136):566\u2013572. https:\/\/doi.org\/10.1080\/21678421.2024.2447922","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"6637","key":"14023_CR42","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1126\/science.abq5622","volume":"379","author":"MW Baughn","year":"2023","unstructured":"Baughn MW et al (2023) Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science 379(6637):1140\u20131149. https:\/\/doi.org\/10.1126\/science.abq5622","journal-title":"Science"},{"issue":"9","key":"14023_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.25382","volume":"102","author":"EJC Thornburg-Suresh","year":"2024","unstructured":"Thornburg-Suresh EJC, Summers DW (2024) Microtubules, membranes, and movement: new roles for stathmin-2 in axon integrity. J Neurosci Res 102(9):e25382. https:\/\/doi.org\/10.1002\/jnr.25382","journal-title":"J Neurosci Res"},{"key":"14023_CR44","unstructured":"Mckenzie H, QurAlis\u2019 Phase 2 data bolster case for genetic approach to sporadic ALS. Biospace. https:\/\/www.biospace.com\/drug-development\/quralis-phase-2-data-bolster-case-for-genetic-approach-to-sporadic-als. Accessed date: 06 Jul 2026"},{"key":"14023_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s44477-025-00013-w","author":"DF Newton","year":"2026","unstructured":"Newton DF et al (2026) Divergent TDP43-regulated and TDP43-independent cryptic splicing in the cortex and spinal cord. Mol Neurodegener Adv. https:\/\/doi.org\/10.1186\/s44477-025-00013-w","journal-title":"Mol Neurodegener Adv"},{"key":"14023_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02780-4","author":"P Torres","year":"2024","unstructured":"Torres P et al (2024) TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-024-02780-4","journal-title":"Acta Neuropathol"},{"issue":"5","key":"14023_CR47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00401-019-02042-8","volume":"138","author":"A Donde","year":"2019","unstructured":"Donde A et al (2019) Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol 138(5):813\u2013826. https:\/\/doi.org\/10.1007\/s00401-019-02042-8","journal-title":"Acta Neuropathol"},{"issue":"6717","key":"14023_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1126\/science.adk2539","volume":"386","author":"OG Wilkins","year":"2024","unstructured":"Wilkins OG et al (2024) Creation of de novo cryptic splicing for ALS and FTD precision medicine. Science 386(6717):61\u201369. https:\/\/doi.org\/10.1126\/science.adk2539","journal-title":"Science"},{"issue":"10","key":"14023_CR49","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","volume":"22","author":"Q Ling","year":"2023","unstructured":"Ling Q, Herstine JA, Bradbury A, Gray SJ (2023) AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov 22(10):789\u2013806. https:\/\/doi.org\/10.1038\/s41573-023-00766-7","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"14023_CR50","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/bph.15148","volume":"178","author":"E Buratti","year":"2021","unstructured":"Buratti E (2021) Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br J Pharmacol 178(6):1298\u20131315. https:\/\/doi.org\/10.1111\/bph.15148","journal-title":"Br J Pharmacol"},{"key":"14023_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102085","volume":"92","author":"A Babazadeh","year":"2023","unstructured":"Babazadeh A, Rayner SL, Lee A, Chung RS (2023) TDP-43 as a therapeutic target in neurodegenerative diseases: focusing on motor neuron disease and frontotemporal dementia. Ageing Res Rev 92:102085. https:\/\/doi.org\/10.1016\/j.arr.2023.102085","journal-title":"Ageing Res Rev"},{"issue":"1","key":"14023_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01592-z","volume":"11","author":"H Riemenschneider","year":"2023","unstructured":"Riemenschneider H et al (2023) Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo. Acta Neuropathol Commun 11(1):112. https:\/\/doi.org\/10.1186\/s40478-023-01592-z","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"14023_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01867-z","volume":"12","author":"E Chevalier","year":"2024","unstructured":"Chevalier E et al (2024) Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS\/FTD. Acta Neuropathol Commun 12(1):156. https:\/\/doi.org\/10.1186\/s40478-024-01867-z","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"14023_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00921-7","volume":"30","author":"Y-L Tseng","year":"2023","unstructured":"Tseng Y-L et al (2023) Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera. J Biomed Sci 30(1):27. https:\/\/doi.org\/10.1186\/s12929-023-00921-7","journal-title":"J Biomed Sci"},{"issue":"9","key":"14023_CR55","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.chembiol.2024.08.010","volume":"31","author":"JA Gregory","year":"2024","unstructured":"Gregory JA, Hickey CM, Chavez J, Cacace AM (2024) New therapies on the horizon: targeted protein degradation in neuroscience. Cell Chem Biol 31(9):1688\u20131698. https:\/\/doi.org\/10.1016\/j.chembiol.2024.08.010","journal-title":"Cell Chem Biol"},{"key":"14023_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106080","volume":"122","author":"KP del Giudice","year":"2024","unstructured":"del Giudice KP et al (2024) Anti-alpha synuclein and anti-tau immunotherapies: can a cocktail approach work? Parkinsonism Relat Disord 122:106080. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106080","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"14023_CR57","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1038\/s41467-025-63031-y","volume":"16","author":"BN Flores","year":"2025","unstructured":"Flores BN et al (2025) Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial. Nat Commun 16(1):7690. https:\/\/doi.org\/10.1038\/s41467-025-63031-y","journal-title":"Nat Commun"},{"issue":"1","key":"14023_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/acn3.51491","volume":"9","author":"JS Katz","year":"2022","unstructured":"Katz JS et al (2022) A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor ALS. Ann Clin Transl Neurol 9(1):50\u201366. https:\/\/doi.org\/10.1002\/acn3.51491","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"14023_CR59","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1083\/jcb.201302044","volume":"201","author":"YR Li","year":"2013","unstructured":"Li YR, King OD, Shorter J, Gitler AD (2013) Stress granules as crucibles of ALS pathogenesis. J Cell Biol 201(3):361\u2013372. https:\/\/doi.org\/10.1083\/jcb.201302044","journal-title":"J Cell Biol"},{"issue":"4","key":"14023_CR60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40142-020-00194-8","volume":"8","author":"JM Gregory","year":"2020","unstructured":"Gregory JM, Fagegaltier D, Phatnani H, Harms MB (2020) Genetics of amyotrophic lateral sclerosis. Curr Genet Med Rep 8(4):121\u2013131. https:\/\/doi.org\/10.1007\/s40142-020-00194-8","journal-title":"Curr Genet Med Rep"},{"issue":"7","key":"14023_CR61","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1021\/acs.jmedchem.3c02422","volume":"67","author":"RA Craig","year":"2024","unstructured":"Craig RA et al (2024) Discovery of DNL343: a potent, selective, and brain-penetrant eIF2B activator designed for the treatment of neurodegenerative diseases. J Med Chem 67(7):5758\u20135782. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02422","journal-title":"J Med Chem"},{"key":"14023_CR62","unstructured":"Denali Therapeutics, Denali therapeutics announces topline results for regimen G evaluating eIF2B agonist DNL343 in the phase 2\/3 HEALEY ALS Platform Trial. GlobeNewswire. https:\/\/www.globenewswire.com\/news-release\/2025\/01\/06\/3005002\/0\/en\/Denali-Therapeutics-Announces-Topline-Results-for-Regimen-G-Evaluating-eIF2B-Agonist-DNL343-in-the-Phase-2-3-HEALEY-ALS-Platform-Trial.html. Accessed date: 30 Mar 2026"},{"key":"14023_CR63","unstructured":"Calico Life Sciences LLC, Calico Provides Update on Fosigotifator in HEALEY ALS Platform Trial. https:\/\/www.calicolabs.com\/press\/calico-statement-on-fosigotifator-in-healey-als-platform-trial\/. Accessed date: 30 Mar 2026"},{"issue":"1","key":"14023_CR64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajhg.2008.12.010","volume":"84","author":"CY Chow","year":"2009","unstructured":"Chow CY et al (2009) Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet 84(1):85\u201388. https:\/\/doi.org\/10.1016\/j.ajhg.2008.12.010","journal-title":"Am J Hum Genet"},{"issue":"7149","key":"14023_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature05876","volume":"448","author":"CY Chow","year":"2007","unstructured":"Chow CY et al (2007) Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 448(7149):68\u201372. https:\/\/doi.org\/10.1038\/nature05876","journal-title":"Nature"},{"issue":"4","key":"14023_CR66","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.cell.2023.01.005","volume":"186","author":"ST Hung","year":"2023","unstructured":"Hung ST et al (2023) PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. Cell 186(4):786-802.e28. https:\/\/doi.org\/10.1016\/j.cell.2023.01.005","journal-title":"Cell"},{"issue":"9","key":"14023_CR67","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1093\/brain\/awae109","volume":"147","author":"S Babu","year":"2024","unstructured":"Babu S et al (2024) Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial. Brain 147(9):2998\u20133008. https:\/\/doi.org\/10.1093\/brain\/awae109","journal-title":"Brain"},{"key":"14023_CR68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138207","author":"L Tejwani","year":"2023","unstructured":"Tejwani L et al (2023) Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43\u2013related neurodegeneration. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI138207","journal-title":"J Clin Invest"},{"issue":"6738","key":"14023_CR69","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/21674","volume":"399","author":"T Ishitani","year":"1999","unstructured":"Ishitani T et al (1999) The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 399(6738):798\u2013802. https:\/\/doi.org\/10.1038\/21674","journal-title":"Nature"},{"issue":"3","key":"14023_CR70","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/ncb2028","volume":"12","author":"T Ishitani","year":"2010","unstructured":"Ishitani T et al (2010) Nemo-like kinase suppresses Notch signalling by interfering with formation of the Notch active transcriptional complex. Nat Cell Biol 12(3):278\u2013285. https:\/\/doi.org\/10.1038\/ncb2028","journal-title":"Nat Cell Biol"},{"issue":"1","key":"14023_CR71","doi-asserted-by":"publisher","first-page":"72","DOI":"10.15252\/embr.201642681","volume":"18","author":"AW Hong","year":"2017","unstructured":"Hong AW et al (2017) Osmotic stress-induced phosphorylation by NLK at Ser128 activates YAP. EMBO Rep 18(1):72\u201386. https:\/\/doi.org\/10.15252\/embr.201642681","journal-title":"EMBO Rep"},{"issue":"7310","key":"14023_CR72","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature09320","volume":"466","author":"AC Elden","year":"2010","unstructured":"Elden AC et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466(7310):1069\u20131075. https:\/\/doi.org\/10.1038\/nature09320","journal-title":"Nature"},{"issue":"7650","key":"14023_CR73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nature22038","volume":"544","author":"LA Becker","year":"2017","unstructured":"Becker LA et al (2017) Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544(7650):367\u2013371. https:\/\/doi.org\/10.1038\/nature22038","journal-title":"Nature"},{"issue":"3","key":"14023_CR74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/ng1196-269","volume":"14","author":"SM Pulst","year":"1996","unstructured":"Pulst SM et al (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 14(3):269\u2013276. https:\/\/doi.org\/10.1038\/ng1196-269","journal-title":"Nat Genet"},{"issue":"8","key":"14023_CR75","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/brain\/awac167","volume":"145","author":"JD Glass","year":"2022","unstructured":"Glass JD et al (2022) ATXN2 intermediate expansions in amyotrophic lateral sclerosis. Brain 145(8):2671\u20132676. https:\/\/doi.org\/10.1093\/brain\/awac167","journal-title":"Brain"},{"issue":"1","key":"14023_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2025-001417","volume":"8","author":"KC Demaegd","year":"2026","unstructured":"Demaegd KC et al (2026) Bi-allelic intermediate ATXN2 repeat expansions are associated with slow progressing, leg-onset familial ALS. BMJ Neurol open 8(1):e001417. https:\/\/doi.org\/10.1136\/bmjno-2025-001417","journal-title":"BMJ Neurol open"},{"key":"14023_CR77","doi-asserted-by":"publisher","DOI":"10.1101\/2025.11.24.690282","author":"D Gastaldo","year":"2025","unstructured":"Gastaldo D et al (2025) Ataxin-2 coordinates neuronal and glial pathways to promote neuroprotection. bioRxiv. https:\/\/doi.org\/10.1101\/2025.11.24.690282","journal-title":"SSRN"},{"issue":"5","key":"14023_CR78","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1212\/WNL.0000000000006855","volume":"92","author":"RPA van Eijk","year":"2019","unstructured":"van Eijk RPA et al (2019) Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 92(5):e451\u2013e460. https:\/\/doi.org\/10.1212\/WNL.0000000000006855","journal-title":"Neurology"},{"key":"14023_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12813-3","author":"RPA van Eijk","year":"2025","unstructured":"van Eijk RPA et al (2025) Attrition and discontinuation in amyotrophic lateral sclerosis clinical trials: a meta-analysis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-024-12813-3","journal-title":"J Neurol"},{"issue":"4","key":"14023_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061177","volume":"8","author":"JD Berry","year":"2013","unstructured":"Berry JD et al (2013) Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS ONE 8(4):e61177. https:\/\/doi.org\/10.1371\/journal.pone.0061177","journal-title":"PLoS ONE"},{"key":"14023_CR81","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/CLEP.S153196","volume":"10","author":"RP van Eijk","year":"2018","unstructured":"van Eijk RP, Eijkemans MJ, Rizopoulos D, van den Berg LH, Nikolakopoulos S (2018) Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol 10:333\u2013341. https:\/\/doi.org\/10.2147\/CLEP.S153196","journal-title":"Clin Epidemiol"},{"issue":"9","key":"14023_CR82","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214937","volume":"106","author":"DN Weemering","year":"2026","unstructured":"Weemering DN, van Unnik JWJ, Genge A, van den Berg LH, van Eijk RPA (2026) Heterogeneity in the analysis of the ALSFRS-R in ALS clinical trials and its effect on the validity and precision of trial conclusions. Neurology 106(9):e214937. https:\/\/doi.org\/10.1212\/WNL.0000000000214937","journal-title":"Neurology"},{"issue":"12","key":"14023_CR83","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamaneurol.2022.3282","volume":"79","author":"JM Shefner","year":"2022","unstructured":"Shefner JM et al (2022) Amyotrophic lateral sclerosis clinical trials and interpretation of functional end points and fluid biomarkers: a review. JAMA Neurol 79(12):1312\u20131318. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3282","journal-title":"JAMA Neurol"},{"issue":"9","key":"14023_CR84","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1212\/WNL.0000000000002251","volume":"86","author":"RS Bedlack","year":"2016","unstructured":"Bedlack RS et al (2016) How common are ALS plateaus and reversals? Neurology 86(9):808\u2013812. https:\/\/doi.org\/10.1212\/WNL.0000000000002251","journal-title":"Neurology"},{"issue":"4","key":"14023_CR85","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s13311-022-01271-2","volume":"19","author":"CN Fournier","year":"2022","unstructured":"Fournier CN (2022) Considerations for amyotrophic lateral sclerosis (ALS) clinical trial design. Neurotherapeutics 19(4):1180\u20131192. https:\/\/doi.org\/10.1007\/s13311-022-01271-2","journal-title":"Neurotherapeutics"},{"key":"14023_CR86","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2026.2659128","author":"S Yusuf","year":"2026","unstructured":"Yusuf S, Allen MD, Kang H, Phillips DE, Genge A (2026) Opportunities and challenges related to participant stratification and cohort enrichment in ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. https:\/\/doi.org\/10.1080\/21678421.2026.2659128","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"14023_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2026.125733","volume":"481","author":"E Nomura","year":"2026","unstructured":"Nomura E et al (2026) The utility of Gold Coast criteria for amyotrophic lateral sclerosis. J Neurol Sci 481:125733. https:\/\/doi.org\/10.1016\/j.jns.2026.125733","journal-title":"J Neurol Sci"},{"issue":"8","key":"14023_CR88","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.clinph.2020.04.005","volume":"131","author":"JM Shefner","year":"1975","unstructured":"Shefner JM et al (1975) A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 131(8):1975\u20131978. https:\/\/doi.org\/10.1016\/j.clinph.2020.04.005","journal-title":"Clin Neurophysiol"},{"issue":"8","key":"14023_CR89","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/jnnp-2022-328823","volume":"93","author":"AD de Jongh","year":"2022","unstructured":"de Jongh AD et al (2022) Characterising ALS disease progression according to El Escorial and Gold Coast criteria. J Neurol Neurosurg Psychiatry 93(8):865\u2013870. https:\/\/doi.org\/10.1136\/jnnp-2022-328823","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"14023_CR90","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/WCO.0000000000001302","volume":"37","author":"HC Timmins","year":"2024","unstructured":"Timmins HC, Thompson AE, Kiernan MC (2024) Diagnostic criteria for amyotrophic lateral sclerosis. Curr Opin Neurol 37(5):570\u2013576. https:\/\/doi.org\/10.1097\/WCO.0000000000001302","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"14023_CR91","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/nejmoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni S et al (2020) Trial of sodium phenylbutyrate\u2013taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 383(10):919\u2013930. https:\/\/doi.org\/10.1056\/nejmoa1916945","journal-title":"N Engl J Med"},{"issue":"1","key":"14023_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph14010029","volume":"14","author":"H Cho","year":"2021","unstructured":"Cho H, Shukla S (2021) Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis. Pharmaceuticals (Basel) 14(1):1\u201314. https:\/\/doi.org\/10.3390\/ph14010029","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3\u20134","key":"14023_CR93","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/21678421.2023.2285443","volume":"25","author":"MA Din Abdul Jabbar","year":"2024","unstructured":"Din Abdul Jabbar MA et al (2024) Predicting amyotrophic lateral sclerosis (ALS) progression with machine learning. Amyotroph Lateral Scler Frontotemporal Degener 25(3\u20134):242\u2013255. https:\/\/doi.org\/10.1080\/21678421.2023.2285443","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"14023_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells12040597","volume":"12","author":"I Cordts","year":"2023","unstructured":"Cordts I et al (2023) TDP-43 proteinopathy specific biomarker development. Cells 12(4):1\u201324. https:\/\/doi.org\/10.3390\/cells12040597","journal-title":"Cells"},{"key":"14023_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.663637","volume":"12","author":"Y Ren","year":"2021","unstructured":"Ren Y et al (2021) TDP-43 and phosphorylated TDP-43 levels in paired plasma and CSF samples in amyotrophic lateral sclerosis. Front Neurol 12:663637. https:\/\/doi.org\/10.3389\/fneur.2021.663637","journal-title":"Front Neurol"},{"issue":"12","key":"14023_CR96","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/acn3.50943","volume":"6","author":"T Kasai","year":"2019","unstructured":"Kasai T et al (2019) Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. Ann Clin Transl Neurol 6(12):2489\u20132502. https:\/\/doi.org\/10.1002\/acn3.50943","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"14023_CR97","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00441-022-03595-z","volume":"392","author":"HG Standke","year":"2023","unstructured":"Standke HG, Kraus A (2023) Seed amplification and RT-QuIC assays to investigate protein seed structures and strains. Cell Tissue Res 392(1):323\u2013335. https:\/\/doi.org\/10.1007\/s00441-022-03595-z","journal-title":"Cell Tissue Res"},{"issue":"2","key":"14023_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/braincomms\/fcaa142","volume":"2","author":"C Scial\u00f2","year":"2020","unstructured":"Scial\u00f2 C et al (2020) TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Commun 2(2):1\u201314. https:\/\/doi.org\/10.1093\/braincomms\/fcaa142","journal-title":"Brain Commun"},{"issue":"734","key":"14023_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.adg7162","volume":"16","author":"S Seddighi","year":"2024","unstructured":"Seddighi S et al (2024) Mis-spliced transcripts generate de novo proteins in TDP-43\u2013related ALS\/FTD. Sci Transl Med 16(734):1\u201317. https:\/\/doi.org\/10.1126\/scitranslmed.adg7162","journal-title":"Sci Transl Med"},{"issue":"2","key":"14023_CR100","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41591-023-02788-5","volume":"30","author":"KE Irwin","year":"2024","unstructured":"Irwin KE et al (2024) A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS\u2013FTD. Nat Med 30(2):382\u2013393. https:\/\/doi.org\/10.1038\/s41591-023-02788-5","journal-title":"Nat Med"},{"issue":"1","key":"14023_CR101","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000009559","volume":"95","author":"M Benatar","year":"2020","unstructured":"Benatar M et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95(1):59\u201369. https:\/\/doi.org\/10.1212\/WNL.0000000000009559","journal-title":"Neurology"},{"issue":"2","key":"14023_CR102","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/nejmoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T et al (2020) Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383(2):109\u2013119. https:\/\/doi.org\/10.1056\/nejmoa2003715","journal-title":"N Engl J Med"},{"issue":"7","key":"14023_CR103","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1093\/brain\/awac394","volume":"146","author":"M Benatar","year":"2023","unstructured":"Benatar M, Wuu J, Turner MR (2023) Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain 146(7):2711\u20132716. https:\/\/doi.org\/10.1093\/brain\/awac394","journal-title":"Brain"},{"key":"14023_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/genes15040496","author":"P Shahim","year":"2024","unstructured":"Shahim P et al (2024) Neurofilaments in sporadic and familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. Genes. https:\/\/doi.org\/10.3390\/genes15040496","journal-title":"Genes"},{"issue":"10","key":"14023_CR105","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70382","volume":"32","author":"K Obara","year":"2025","unstructured":"Obara K et al (2025) Diagnostic and prognostic value of blood and cerebrospinal fluid biomarkers in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Eur J Neurol 32(10):e70382. https:\/\/doi.org\/10.1111\/ene.70382","journal-title":"Eur J Neurol"},{"issue":"2","key":"14023_CR106","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ana.26860","volume":"95","author":"M Benatar","year":"2024","unstructured":"Benatar M et al (2024) Biomarker qualification for neurofilament light chain in amyotrophic lateral sclerosis: theory and practice. Ann Neurol 95(2):211\u2013216. https:\/\/doi.org\/10.1002\/ana.26860","journal-title":"Ann Neurol"},{"key":"14023_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1269406","volume":"14","author":"M Flotats-Bastardas","year":"2023","unstructured":"Flotats-Bastardas M et al (2023) Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi. Front Neurol 14:1269406. https:\/\/doi.org\/10.3389\/fneur.2023.1269406","journal-title":"Front Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14023-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14023-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14023-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:49:42Z","timestamp":1786348182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14023-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":107,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["14023"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14023-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Carlos Estevez-Fraga, Marcos Costa, Tariq Afroz, Ana Jovi\u010dic, Felix Yeh, Peter McColgan, and Alexander McCampbell are full-time employees of Roche Products Ltd, Genentech Inc and Hoffmann-La Roche, members of the Roche Group. Rodrigo Alvarez-Velasco has received fees from UCB, Argenx, and Alexion. Andrea Malaspina has acted as an adviser for Roche and Accure Therapeutics, has given a Lecture to Pfizer and has been part of biomarker data licencing to Biogen. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. This review reflects the authors\u2019 scientific and translational perspectives on TDP-43 therapeutic development in ALS, informed by experience across academia, biomarker research, and drug development.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"498"}}